General view of Swiss pharmaceutical company Roche's general annual shareholders meeting in Basel
Michael Buholzer  /  REUTERS
General view of Swiss pharmaceutical company Roche's general annual shareholders meeting in Basel, March 10, 2009. REUTERS/Michael Buholzer
updated 3/26/2009 2:26:13 AM ET 2009-03-26T06:26:13

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG said on Thursday it controlled a total of 96.2 percent of Genentech shares after completing its tender offer for the 44 percent stake it did not already own.

Roche said remaining holders of Genentech shares would revive $95 a share. Genentech will cease to be traded on the New York Stock Exchange, Roche said.

After a drawn-out battle, the Swiss drugmaker finally clinched a deal earlier this year for part of the U.S. biotech group it did not own for $46.8 billion.

(Reporting by Lisa Jucca; editing by John Stonestreet)

Copyright 2012 Thomson Reuters. Click for restrictions.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.40%
$30K home equity loan FICO 5.80%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.70%
13.70%
Cash Back Cards 17.66%
17.91%
Rewards Cards 17.05%
17.17%
Source: Bankrate.com